Onpattro annual cost of therapy?

How much does Onpattro cost per year?

Onpattro (patisiran) is a prescription medication approved for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). The annual cost of therapy with Onpattro can vary depending on several factors, including the patient's insurance status, dosage, and treatment duration.

According to a report by DrugPatentWatch.com , the annual cost of Onpattro can range from approximately $89,900 to $112,800 per year. This estimate is based on a treatment duration of 4 doses per year, with each dose costing around $22,475 to $28,200.

Why is Onpattro so expensive?

Several factors contribute to the high cost of Onpattro. The cost of developing and manufacturing the medication is a major factor. Additionally, Onpattro is a rare disease treatment, which can lead to higher prices due to the smaller market size and limited competition. Furthermore, the medication requires a specialized delivery method, which may also contribute to its high cost.

Is Onpattro covered by insurance?

Coverage of Onpattro by insurance plans can vary. Many insurers, including Medicare, Medicaid, and commercial plans, may cover the medication for patients with hATTR amyloidosis. However, the level of coverage and out-of-pocket costs can differ significantly depending on the specific plan.

Is there a generic version of Onpattro available?

Currently, there is no generic version of Onpattro available. Alnylam Pharmaceuticals, the manufacturer of Onpattro, has a patent on the medication that will not expire until [2028](Source: DrugPatentWatch.com ). This means that patients may be required to pay the full price of Onpattro until the patent expires.

Sources:

1. DrugPatentWatch.com
2. Alnylam Pharmaceuticals' website
3. Center for Medicare and Medicaid Services' coverage determination report